Qilu Hospital of Shandong University
π¨π³China
- Country
- π¨π³China
- Ownership
- Private
- Established
- 1890-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.qiluhospital.com
Clinical Trials
250
Active:10
Completed:31
Trial Phases
6 Phases
Early Phase 1:4
Phase 1:8
Phase 2:24
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (149 trials with phase data)β’ Click on a phase to view related trials
Not Applicable
85 (57.0%)Phase 4
25 (16.8%)Phase 2
24 (16.1%)Phase 1
8 (5.4%)Early Phase 1
4 (2.7%)Phase 3
3 (2.0%)The Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With CHD Complicated by Sarcopenia
Not Applicable
Not yet recruiting
- Conditions
- Coronary DiseaseSarcopenia
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 100
- Registration Number
- NCT07197463
Effects of Different Modes of Action Observation Therapy on Swallowing Function After Stroke: a Study Based on fNIRS
Not Applicable
Recruiting
- Conditions
- Stroke
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 90
- Registration Number
- NCT07184892
- Locations
- π¨π³
Qilu Hospital, Jinan, Shandong, China
Cost Profile and Budget Implications of Rechargeable Versus Non-rechargeable Sacral Neuromodulation Devices for Neurogenic Lower Urinary Tract Dysfunction
Not yet recruiting
- Conditions
- Rechargeable Sacral Neuromodulation DeviceNeurogenic Lower Urinary Tract Dysfunction
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 268
- Registration Number
- NCT07173517
- Locations
- π¨π³
Qilu Hospital, Jinan, Shandong, China
The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC
Not Applicable
Not yet recruiting
- Conditions
- Recurrent Cervical Cancer
- Interventions
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 33
- Registration Number
- NCT07172217
- Locations
- π¨π³
Qilu Hospital of Shandong University, Ji'an, Shandong, China
Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
Not Applicable
Recruiting
- Conditions
- Prostate Cancer
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 116
- Registration Number
- NCT07172685
- Locations
- π¨π³
Qilu hospital, Jinan, Shandong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 49
- Next
News
No news found